Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine
Status:
Active, not recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
HOLA is a prospective, randomized (1:1), hybrid type (implementation-effectiveness), phase
IV, double arm, open label, multicentric study including virologically suppressed HIVinfected
subjects who start or are currently under treatment with the LA antiretroviral combination
CAB+RPV, to evaluate the out-of-hospital administration of this combination in terms of
acceptability, appropriateness, feasibility and satisfaction.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia